GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » St Jude Medical Inc (NYSE:STJ) » Definitions » Beneish M-Score

St Jude Medical (St Jude Medical) Beneish M-Score : 0.00 (As of Apr. 25, 2024)


View and export this data going back to 1977. Start your Free Trial

What is St Jude Medical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for St Jude Medical's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of St Jude Medical was 0.00. The lowest was 0.00. And the median was 0.00.


St Jude Medical Beneish M-Score Historical Data

The historical data trend for St Jude Medical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

St Jude Medical Beneish M-Score Chart

St Jude Medical Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.73 -2.79 -2.44 -2.75 -2.45

St Jude Medical Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.77 -2.45 -2.44 -2.47 -2.34

Competitive Comparison of St Jude Medical's Beneish M-Score

For the Medical Devices subindustry, St Jude Medical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


St Jude Medical's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, St Jude Medical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where St Jude Medical's Beneish M-Score falls into.



St Jude Medical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of St Jude Medical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0156+0.528 * 1.0459+0.404 * 1.5293+0.892 * 1.0765+0.115 * 0.831
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0965+4.679 * -0.03054-0.327 * 0.994
=-2.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep16) TTM:Last Year (Sep15) TTM:
Total Receivables was $1,290 Mil.
Revenue was 1499 + 1562 + 1448 + 1447 = $5,956 Mil.
Gross Profit was 1004 + 1066 + 961 + 946 = $3,977 Mil.
Total Current Assets was $2,816 Mil.
Total Assets was $12,541 Mil.
Property, Plant and Equipment(Net PPE) was $1,336 Mil.
Depreciation, Depletion and Amortization(DDA) was $415 Mil.
Selling, General, & Admin. Expense(SGA) was $2,062 Mil.
Total Current Liabilities was $1,457 Mil.
Long-Term Debt & Capital Lease Obligation was $5,403 Mil.
Net Income was 212 + 238 + 95 + 113 = $658 Mil.
Non Operating Income was -2 + -3 + -53 + 7 = $-51 Mil.
Cash Flow from Operations was 442 + 313 + 150 + 187 = $1,092 Mil.
Total Receivables was $1,180 Mil.
Revenue was 1339 + 1410 + 1345 + 1439 = $5,533 Mil.
Gross Profit was 914 + 986 + 950 + 1014 = $3,864 Mil.
Total Current Assets was $4,991 Mil.
Total Assets was $11,125 Mil.
Property, Plant and Equipment(Net PPE) was $1,268 Mil.
Depreciation, Depletion and Amortization(DDA) was $311 Mil.
Selling, General, & Admin. Expense(SGA) was $1,747 Mil.
Total Current Liabilities was $2,858 Mil.
Long-Term Debt & Capital Lease Obligation was $3,264 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1290 / 5956) / (1180 / 5533)
=0.216588 / 0.213266
=1.0156

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3864 / 5533) / (3977 / 5956)
=0.698355 / 0.66773
=1.0459

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2816 + 1336) / 12541) / (1 - (4991 + 1268) / 11125)
=0.668926 / 0.437393
=1.5293

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=5956 / 5533
=1.0765

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(311 / (311 + 1268)) / (415 / (415 + 1336))
=0.19696 / 0.237007
=0.831

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2062 / 5956) / (1747 / 5533)
=0.346206 / 0.315742
=1.0965

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((5403 + 1457) / 12541) / ((3264 + 2858) / 11125)
=0.547006 / 0.550292
=0.994

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(658 - -51 - 1092) / 12541
=-0.03054

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

St Jude Medical has a M-score of -2.34 suggests that the company is unlikely to be a manipulator.


St Jude Medical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of St Jude Medical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


St Jude Medical (St Jude Medical) Business Description

Traded in Other Exchanges
N/A
Address
St Jude Medical Inc was incorporated in Minnesota in 1976. It develops, manufactures and distributes cardiovascular medical devices for the cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Company's two segments are the Implantable Electronic Systems Division and the Cardiovascular and Ablation Technologies Division. The Company's principal products in each business unit are as follows: Implantable Electronic Systems Division (IESD) - tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) - vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, cardiac mapping, navigation and recording systems and ablation systems). Implantable Electronic Systems Division (IESD): IESD is focused on the cardiac rhythm management and neuromodulation therapy areas. Cardiac rhythm management devices include ICDs that provide life-saving therapy to patients suffering from lethal heart conditions, such as sudden cardiac arrest; cardiac resynchronization therapy (CRT) devices to save and improve the lives of patients suffering from heart failure (HF); pacemakers to help patients whose hearts beat too slowly or who suffer from other debilitating cardiac arrhythmias; leads (wires that connect devices to the heart) to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment which are used by physicians and healthcare professionals to program is cardiac rhythm management devices and analyze device data to improve patient management. Neuromodulation product offerings provide neurostimulation treatment in which an implantable device delivers electrical current directly to targeted nerve sites. The Company's commercialized neurostimulation therapies include spinal cord stimulation (SCS) for the treatment of chronic pain, deep brain stimulation (DBS) for treating the symptoms of Parkinson's disease and peripheral nerve stimulation (PNS) for the treatment of chronic migraine headache. A neurostimulation system typically consists of four components: a pulse generator that produces the electrical current and is implanted under the patient's skin; implanted leads that carry the electrical impulses to the targeted nerve sites; an external patient remote control that enables the patient to control his or her therapy within prescribed ranges; and an external clinician pro
Executives
Jeff Fecho officer: VP, Global Quality ONE ST. JUDE MEDICAL DRIVE ST. PAUL MN 55117
Philip Ebeling officer: VP, Chief Technology Officer INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BLVD., SUITE 1600, GOLDEN VALLEY MN 55416
Donald Zurbay officer: VP Finance and CFO C/O ST. JUDE MEDICAL, INC., ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Michael A Rocca director C/O LIGAND PHARMACEUTICALS INCORPORATED, 10275 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Barbara B Hill director
Wendy L Yarno director
Stuart Essig director 311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
John C Heinmiller officer: Executive Vice President ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
John W Brown director STRYKER CORP, 2725 FAIRFIELD ROAD, KALAMAZOO MI 49002
David C Dvorak director C/O ZIMMER INC, PO BOX 708, WARSAW IN 46580
Michael T Rousseau director, officer: Director, President and CEO ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Eric S Fain officer: Group President ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Daniel J Starks director ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Joel Becker officer: President, Americas ONE ST. JUDE MEDICAL DRIVE, ST. PAUL MN 55418
Rohan Hoare officer: President - NMD 100 CYBERONICS BLVD, HOUSTON TX 77058

St Jude Medical (St Jude Medical) Headlines

From GuruFocus

Sarah Ketterer Returns 24 Pct in 2012, Her Top Q4 Buys

By Holly LaFon Holly LaFon 02-25-2013

Richard Perry Buys St. Jude

By Sydnee Gatewood Sydnee Gatewood 08-15-2016

Richard Perry Exits AIG, Time Warner

By Tiziano Frateschi Tiziano Frateschi 11-14-2016